SCHEMBL30329812

SCHEMBL30329812

CNc1cc(C)nc(Nc2cc(O)c3c(c2)OCO3)n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HAVCR2 Q8TDQ0 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ KCNH2 Q12809 1/20 0.40
▸ APOBEC3A P31941 1/20 0.38
▸ APOBEC3G Q9HC16 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ EHMT2 Q96KQ7 12/20 0.38
▸ EHMT1 Q9H9B1 11/20 0.38
▸ LMNA P02545 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ IGF1R P08069 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25166581 1.00 HAVCR2 (0.43) HAVCR2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30329759 0.90 ABCB1 (0.38) HAVCR2ALDH1A1APOBEC3AAPOBEC3GL3MBTL1
SCHEMBL25166156 0.90 ABCB1 (0.38) HAVCR2ALDH1A1APOBEC3AAPOBEC3GL3MBTL1
SCHEMBL30330177 0.85 HAVCR2 (0.41) HAVCR2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL25166431 0.85 HAVCR2 (0.41) HAVCR2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL25166455 0.82 NPC1 (0.38) HAVCR2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30329704 0.82 NPC1 (0.38) HAVCR2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL25166672 0.78 APOBEC3A (0.36) APOBEC3AAPOBEC3GL3MBTL1EHMT2EHMT1
SCHEMBL31107984 0.75 EHMT2 (0.37) HAVCR2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30329819 0.75 EHMT2 (0.37) HAVCR2KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 — — US disclosed
CN-118647610-A Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof 探戈医药股份有限公司 2024-09-13 — — CN disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 — — EP disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 HAVCR2 934/4885KDM4E 420/4885ALDH1A1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback